Evidence map›Paper›PMID 34304287›Full record

Trial reportAnnals of hematology2021

Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study.

Won Seog Kim, Yasuhiro Oki, Seok Jin Kim, Sang Eun Yoon, Kirit M Ardeshna, Yi Lin, Jia Ruan, Pierluigi Porcu, Jonathan E Brammer, Eric D Jacobsen and 19 more

Abstract readClinical Trial, Phase IIMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Annals of hematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Molecular pathogenesis and evolving treatment landscape of extranodal NK/T-cell lymphoma.Proceedings of the Japan Academy. Series B, Physical and biological sciences · 2026
    Review
  5. Article
  6. Adoptive T-cell therapy for virus-associated diseases.Clinical microbiology reviews · 2025
    Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. How we treat NK/T-cell lymphomas.Journal of hematology & oncology · 2022
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Won Seog KimDivision of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, South Korea. wskimsmc@skku.edu.
Yasuhiro OkiGenentech Inc, South San Francisco, CA, USA.
Seok Jin KimDivision of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, South Korea.
Sang Eun YoonDivision of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, South Korea.
Kirit M ArdeshnaUniversity College London Hospitals, London, UK.
Yi LinMayo Clinic, Rochester, MN, USA.
Jia RuanWeill Cornell Medicine and New York Presbyterian Hospital, New York, NY, USA.
Pierluigi PorcuDivision of Hematologic Malignancies and Cellular Therapy, Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.
Jonathan E BrammerDivision of Hematology, Department of Internal Medicine, James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
Eric D JacobsenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Dok Hyun YoonDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Cheolwon SuhDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Felipe SuarezHématologie Adulte, Hôpital Universitaire Necker, Paris, France.
John RadfordManchester Academic Health Science Centre, University of Manchester and the Christie NHS Foundation Trust, Manchester, UK.
Lihua E BuddeHematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA.
Jin Seok KimDepartment of Internal Medicine, Yonsei University College of Medicine, Severance Hospital, Seoul, South Korea.
Emmanuel BachyHematology Department, Hospices Civils de Lyon 1 University, Sud Hospital, Pierre Benite, Lyon, France.
Hun Ju LeeGenentech Inc, South San Francisco, CA, USA.
Catherine M BollardCenter for Cancer and Immunology Research and The George Washington Cancer Center, Children's National Hospital and The George Washington University, Washington, DC, USA.
Arnaud JaccardDepartment of Hematology and National Referral Center for AL Amyloidosis, CHU Limoges, Limoges, France.
Hye Jin KangDepartment of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, South Korea.
Shannon InmanKuur Therapeutics, Houston, TX, USA.
Maryann MurrayTreximo, LLC, Chicago, IL, USA.
Katherin E CombsKuur Therapeutics, Houston, TX, USA.
Daniel Y LeeHouston Methodist Research Institute, Houston, TX, USA.
Ranjana AdvaniStanford Cancer Center, Stanford, CA, USA.
Kurt C GunterKuur Therapeutics, Houston, TX, USA.
Cliona M RooneyCenter for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital, Houston, TX, USA.
Helen E HeslopCenter for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital, Houston, TX, USA.

Funding

Institutional Career Development CoreKL2TR002734 · NCATS · OHIO STATE UNIVERSITY · PI CARNES, CYNTHIA A · 2018 to 2022
$2.7M
CSRD VA 1
6 · The paper itself

Abstract

We conducted a phase II clinical trial to develop an autologous EBV-specific T cell product (baltaleucel T) for advanced, relapsed ENKTL. Among 47 patients who provided whole blood starting material for manufacturing the product, 15 patients received a median of 4 doses of baltaleucel T. Thirty-two (68%) patients did not receive baltaleucel-T due to manufacturing failure, rapid disease progression, and death. Of the 15 patients, 10 patients had measurable disease at baseline (salvage cohort), and 5 patients had no disease at baseline assessment (adjuvant cohort). In the 15 patients, the median follow-up duration was 10.2 months (range 2.0-23.5 months), median progression-free survival (PFS) was 3.9 months, and the median overall survival (OS) was not reached. Patients in the salvage cohort achieved a 30% complete response (CR) and a 50% overall response rate (ORR). In the adjuvant cohort, disease progression was reported in three patients and two patients did not relapse during study follow-up. When we compared survival outcomes of seven responders and eight non-responders, the PFS (P = 0.001) and OS (P = 0.014) of responders proved statistically superior to that of non-responders. Baltaleucel-T was well tolerated. We have performed a phase II clinical trial of autologous EBV-specific T cell treatment (baltaleucel-T) in R/R ENKTL. Autologous EBV-specific T cells were well tolerated and demonstrated single-agent activity in R/R ENTKL.

Indexed as

AdultAgedEpstein-Barr Virus InfectionsFemaleHerpesvirus 4, HumanHumansImmunotherapy, AdoptiveLymphoma, Extranodal NK-T-CellMaleMiddle AgedT-LymphocytesTreatment OutcomeYoung AdultEpstein-Barr virusExtranodal NK/T-cell lymphomaImmunotherapyRelapsed and refractory

Identifiers

PMID34304287

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.